Changes in Hong Kong stocks | McPharmaceutical-B (02335) rose more than 10% to usher in progress, and the development of a variety of innovative drugs ushered in progress MT1013 completed Phase III follow-up of all test subjects

The Zhitong Finance App learned that Maike Pharmaceutical-B (02335) increased by more than 10%. As of press release, it rose 10.13% to HK$23.48, with a turnover of HK$186 million.

According to the news, the research and development of a number of innovative drugs under Maike Pharmaceutical has ushered in new progress. On November 9, the drug clinical trial registration and information disclosure platform showed that XTL6001, developed independently by McPharmaceuticals, launched a phase II clinical trial for overweight and obese people in China. The company announced on the same day that in the critical phase III clinical trial of the core product MT1013, all enrolled participants have completed the study, treatment and follow-up procedures specified in all trial plans, and have left the group.

It is worth noting that Maike Pharmaceutical recently received the first funding for a major national science and technology project, marking the official implementation of the national project to support MT200605 research and development, and the one-time approval of MT200605 phase III clinical ethics. Currently, Maike Pharmaceuticals has formed an innovative pharmaceutical pipeline represented by MT1013 as the core product and the three key products XTL6001, MT1002, and MT200605.